126 related articles for article (PubMed ID: 38279366)
21. Human disease phenotypes associated with mutations in TREX1.
Rice GI; Rodero MP; Crow YJ
J Clin Immunol; 2015 Apr; 35(3):235-43. PubMed ID: 25731743
[TBL] [Abstract][Full Text] [Related]
22. Biochemical properties of mammalian TREX1 and its association with DNA replication and inherited inflammatory disease.
Lindahl T; Barnes DE; Yang YG; Robins P
Biochem Soc Trans; 2009 Jun; 37(Pt 3):535-8. PubMed ID: 19442247
[TBL] [Abstract][Full Text] [Related]
23. Heterozygous TREX1 p.Asp18Asn mutation can cause variable neurological symptoms in a family with Aicardi-Goutieres syndrome/familial chilblain lupus.
Abe J; Izawa K; Nishikomori R; Awaya T; Kawai T; Yasumi T; Hiragi N; Hiragi T; Ohshima Y; Heike T
Rheumatology (Oxford); 2013 Feb; 52(2):406-8. PubMed ID: 22829693
[No Abstract] [Full Text] [Related]
24. A nationwide survey of Aicardi-Goutières syndrome patients identifies a strong association between dominant TREX1 mutations and chilblain lesions: Japanese cohort study.
Abe J; Nakamura K; Nishikomori R; Kato M; Mitsuiki N; Izawa K; Awaya T; Kawai T; Yasumi T; Toyoshima I; Hasegawa K; Ohshima Y; Hiragi T; Sasahara Y; Suzuki Y; Kikuchi M; Osaka H; Ohya T; Ninomiya S; Fujikawa S; Akasaka M; Iwata N; Kawakita A; Funatsuka M; Shintaku H; Ohara O; Ichinose H; Heike T
Rheumatology (Oxford); 2014 Mar; 53(3):448-58. PubMed ID: 24300241
[TBL] [Abstract][Full Text] [Related]
25. Defects in DNA degradation revealed in crystal structures of TREX1 exonuclease mutations linked to autoimmune disease.
Bailey SL; Harvey S; Perrino FW; Hollis T
DNA Repair (Amst); 2012 Jan; 11(1):65-73. PubMed ID: 22071149
[TBL] [Abstract][Full Text] [Related]
26. Aicardi-Goutières syndrome protein TREX1 suppresses L1 and maintains genome integrity through exonuclease-independent ORF1p depletion.
Li P; Du J; Goodier JL; Hou J; Kang J; Kazazian HH; Zhao K; Yu XF
Nucleic Acids Res; 2017 May; 45(8):4619-4631. PubMed ID: 28334850
[TBL] [Abstract][Full Text] [Related]
27. Different Clinical Manifestations of Three Prime Repair Exonuclease 1 Mutation: A Case Series.
Incecik F; Balci S; Kisla Ekinci RM; Herguner OM; Bisgin A; Yilmaz M
Ann Indian Acad Neurol; 2020; 23(5):699-703. PubMed ID: 33623276
[TBL] [Abstract][Full Text] [Related]
28. New roles for the major human 3'-5' exonuclease TREX1 in human disease.
Kavanagh D; Spitzer D; Kothari PH; Shaikh A; Liszewski MK; Richards A; Atkinson JP
Cell Cycle; 2008 Jun; 7(12):1718-25. PubMed ID: 18583934
[TBL] [Abstract][Full Text] [Related]
29. The Arg-62 residues of the TREX1 exonuclease act across the dimer interface contributing to catalysis in the opposing protomers.
Fye JM; Coffin SR; Orebaugh CD; Hollis T; Perrino FW
J Biol Chem; 2014 Apr; 289(16):11556-11565. PubMed ID: 24616097
[TBL] [Abstract][Full Text] [Related]
30. Targeted Treatment of TREX1 Chilblain Lupus and Other Interferonopathies-Taming T REX.
Damsky W; King BA
JAMA Dermatol; 2019 Mar; 155(3):283-284. PubMed ID: 30673073
[No Abstract] [Full Text] [Related]
31. Type I interferonopathies with novel compound heterozygous TREX1 mutations in two siblings with different symptoms responded to tofacitinib.
Zhang S; Song J; Yang Y; Miao H; Yang L; Liu Y; Zhang X; Liu Y; Wang T
Pediatr Rheumatol Online J; 2021 Jan; 19(1):1. PubMed ID: 33407657
[TBL] [Abstract][Full Text] [Related]
32. Systemic involvement in TREX1-associated familial chilblain lupus.
Günther C; Hillebrand M; Brunk J; Lee-Kirsch MA
J Am Acad Dermatol; 2013 Oct; 69(4):e179-81. PubMed ID: 24034389
[No Abstract] [Full Text] [Related]
33. The Overlap between Genetic Susceptibility to COVID-19 and Skin Diseases.
Jabalameli N; Rajabi F; Firooz A; Rezaei N
Immunol Invest; 2022 May; 51(4):1087-1094. PubMed ID: 33494631
[TBL] [Abstract][Full Text] [Related]
34. Deregulated type I IFN response in TREX1-associated familial chilblain lupus.
Peschke K; Friebe F; Zimmermann N; Wahlicht T; Schumann T; Achleitner M; Berndt N; Luksch H; Behrendt R; Lee-Kirsch MA; Roers A; Günther C
J Invest Dermatol; 2014 May; 134(5):1456-1459. PubMed ID: 24270665
[No Abstract] [Full Text] [Related]
35. Chilblain lupus erythematosus--a review of literature.
Hedrich CM; Fiebig B; Hauck FH; Sallmann S; Hahn G; Pfeiffer C; Heubner G; Lee-Kirsch MA; Gahr M
Clin Rheumatol; 2008 Aug; 27(8):949-54. PubMed ID: 18543054
[TBL] [Abstract][Full Text] [Related]
36. Familial Chilblain Lupus - What Can We Learn from Type I Interferonopathies?
Fiehn C
Curr Rheumatol Rep; 2017 Aug; 19(10):61. PubMed ID: 28844088
[TBL] [Abstract][Full Text] [Related]
37. TREX1 variants in Sjogren's syndrome related lymphomagenesis.
Nezos A; Makri P; Gandolfo S; De Vita S; Voulgarelis M; Crow MK; Mavragani CP
Cytokine; 2020 Aug; 132():154781. PubMed ID: 31326279
[TBL] [Abstract][Full Text] [Related]
38. cGAS activation causes lupus-like autoimmune disorders in a TREX1 mutant mouse model.
Xiao N; Wei J; Xu S; Du H; Huang M; Zhang S; Ye W; Sun L; Chen Q
J Autoimmun; 2019 Jun; 100():84-94. PubMed ID: 30872080
[TBL] [Abstract][Full Text] [Related]
39. The TREX1 exonuclease R114H mutation in Aicardi-Goutières syndrome and lupus reveals dimeric structure requirements for DNA degradation activity.
Orebaugh CD; Fye JM; Harvey S; Hollis T; Perrino FW
J Biol Chem; 2011 Nov; 286(46):40246-54. PubMed ID: 21937424
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
